The Food and Drug Administration will accelerate its review of psychedelic drugs developed by Compass Pathways, Usona Institute and Transcend Therapeutics for mental disorders as part of the Trump administration’s plan to increase access to controversial but promising drugs.
The agency will specifically grant priority review vouchers to Compass’ psilocybin product for treatment-resistant depression, Usona’s drug-like drug for major depressive disorder, and Transcend’s MDMA-like drug for post-traumatic stress disorder.
The FDA identified the drugs that received vouchers, but not the companies that developed them. Compass confirmed it received the vouchers, but the other companies were identified by people familiar with the matter.
STAT+ exclusive story
Already have an account? Log in
This article is exclusive to STAT+ subscribers
Unlock this article and get in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in
Individual plan Group plan See all plans
To read the rest of this story, subscribe to STAT+.
Subscribe
Source link
